Objective: To investigate the effect of fluorescent dye labeling on the targeting capabilities of 111 In-(DTPA) n -trastuzumab-(IRDye 800) m .
Introduction
Precision medicine, selecting appropriate and optimal therapies based on the context of a patient's genetic content or other molecular analysis, has become increasingly important in the treatment strategies of cancer (1) . Nuclear medicine and optical fl uorescence imaging techniques provide powerful non-invasive imaging capability for the assessment of biomarker overexpression in tumor cells, including tissues that may not be amenable to detect with conventional imaging modalities (2, 3) . However, the low spatial resolution at the cellular level limits the ability of nuclear medicine techniques to detect microscopic lesions. Furthermore, low penetration depth is a key limitation of optical imaging modalities (4) . The use of dual-modality imaging probes confers an unprecedented leverage by harnessing the complementary advantages and outweighing the respective limitations of these techniques (5, 6) .
Trastuzumab is a humanized anti-human epidermal growth factor receptor 2 (HER2) antibody that is approved for the treatment of breast cancer (7, 8) . HER2 overexpression, reported in 25%-30% of all breast cancers, is associated with a poor prognosis and aggressive tumor attributes (9) . The reported conservation and upregulation of HER2 make trastuzumab a promising therapeutic modality for targeting metastatic disease in patients with HER2(+) breast cancer (10) .
Recent studies have evaluated dual-labeling of trastuzumab for nuclear imaging using positron emission tomography (PET) or single photon emission computed tomography (SPECT) radionuclides as well as for near-infrared (NIR) fluorescence imaging at excitation wave lengths >750 nm (11) (12) (13) . A comparison of the nuclear and NIR fluorescence images of xenografts following the administration of dual-labeled peptide and antibody showed comparable target-to-background ratios (indicative of comparable sensitivities and stable dual-labeling) but a higher signal-to-noise ratio (SNR) of NIR fl uorescence, which is consistent with the increased photon count rates possible with fl uorescence. However, the synthetic complexity and the effect of the fl uorescent dye on the biodistribution of the imaging agent are two major challenges to the use of dualmodality imaging (14) .
Here, we describe a method for dual-labeling of an antibody with a NIR fluorophore, IRDye 800CW, and diethylenetriaminepentaacetic acid (DTPA) for the chelation of 111 In. The stearic effect of conjugation of a biomodal imaging tag to trastuzumab was investigated by altering the molar ratios of chelator/near-infrared dye to protein. The stability, binding affinity and targeting property of the dual-labeled imaging agent were assessed both in vitro and in vivo. 
Materials and methods

Materials
Cell culture
Human breast cancer SKBR-3 cells with a stable overexpression of HER2 (American Type Culture Collection) were cultured in Dulbecco's minimal essential medium (DMEM)/F-12 (Invitrogen) with 10% fetal bovine serum (Hyclone) in a humidifi ed incubator at 37 °C with 5% CO 2 .
Preparation of trastuzumab-based conjugate
Conjugation of DTPA to trastuzumab
Trastuzumab was dissolved in 50 mmol/L NaHCO 3 (pH 8.0) at a concentration of 20 mg/mL and incubated with p-SCN-Bn-DTPA at room temperature (RT) for 1 h in varying DTPAto-trastuzumab molar ratios (1:1 to 10:1). The final molar ratio of DTPA to protein, "n", was determined as described by Hnatowich et al. (15) . Unbound DTPA was removed using ultrafiltration (molecular weight cut-off 50 kD, Millipore).
Final protein concentrations were determined by ultraviolet absorbance at 280 nm.
Conjugation of IRDye 800CW to DTPA-trastuzumab (DTPA) 2 -trastuzumab was conjugated with IRDye 800CW in varying IRDye 800CW-to-antibody molar ratios of 1:1 to 10:1 as per the instructions provided by LI-COR Biosciences. The number of final dye molecules per protein molecule (dye-toprotein ratio, "m") and protein concentration were calculated by measuring absorbance with a UV-Vis spectrophotometer (Beckman Coulter) at 280 nm and 780 nm (11) .
Assessment of purity of (DTPA) n -trastuzumab-(IRDye 800) m Aliquots of 0.1-0.2 ng conjugates mixed with Laemmli sample buffer (without beta-mercaptoethanol) were loaded onto 4%-12% Tris-glycine acrylamide gels (Bio-Rad). Gels were run until the bromophenol blue reached approximately 10 mm from the bottom of gels, and subsequently imaged using a LI-COR Odyssey infrared imaging system, and 16-bit tif fi les were analyzed using ImageJ software (NIH, MD). The identifi cation of the region of interest (ROI) of a pre-defined pixel size for each gel band and quantifi cation of fl uorescent intensity levels were performed.
Flow cytometry
In brief, 0.3×10 6 
111
In radiolabeling yields were monitored by silica gel instant thin-layer chromatography (SG-ITLC, EMD Chemicals) using a Bioscan System 200 Imaging Scanner. The radiolabeling efficiency was calculated using WinScan software.
Stability analysis was performed by adding 1 mCi 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) m to 1 mL of PBS or human serum (Millipore). The mixtures were then incubated at 37 °C for 24 h. Aliquots at each time point were run on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) system described above. The radiochemical and fluorescent purity were analyzed using a Bioscan System 200 Imaging Scanner and a LI-COR Odyssey infrared imaging system, respectively.
Lindmo assay
The binding affinity of 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) m and 111 In-(DTPA) 2 -transtuzumab was compared via the Lindmo assay as described previously (11) . In brief, a fixed amount of trastuzumab-based conjugate (5 pmol) was added to increasing concentrations of SKBR-3 cells (from 0.1×10 6 to 2×10 6 in 0.5 mL) and incubated for 1 h. To determine nonspecific cell binding, aliquots of cells were incubated with radiolabeled conjugates in the presence of 0.5 µmol unlabeled trastuzumab. The cell pellets were measured using a gamma counter. Specific binding was calculated as the ratio of the cell bound to the total radioactivity applied minus nonspecifi c binding. The immunoreactive fraction was calculated using OriginLab Microcal software.
Internalization studies
In brief, approximately 2.5 pmol of trastuzumab-based conjugate was added to pretreated SKBR-3 cells with an overexpression of HER2 and incubated (in triplicate) for 4h and 24 h at 37 °C. A 1,000-fold excess of each blocking agent was used to determine nonspecifi c internalization. At each time point, the internalization was stopped by the removal of the medium followed by washing the cells with ice-cold 0.01 mol/L PBS (pH 7.4). The cells were then treated for 5 min (three times) with ice-cold glycine buffer (0.05 mol/L glycine solution, and pH adjusted to 2.8 with 1 mol/L HCl) to distinguish between cell surface-bound (acidreleasable) and internalized (acid-resistant) radiolabeled antibodies. The internalized fluorescence intensity was measured using Odyssey infrared imaging system and the results were plotted with ImageJ software. In-(DTPA) 2 -trastuzumab-(IRDye 800) 3 , and 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) 5 were compared to that of 111 In-(DTPA) 2 -trastuzumab. Groups of 3-4 athymic female nude mice bearing SKBR-3 cell tumors were used for all experiments. The mice were administered 20 µg of 111 In-labeled conjugates (approximately 1.48 mBq) in 0.1 mL of 0.9% NaCl via the lateral tail vein. For the determination of nonspecific uptake in the tumor tissue, another group of 3 mice were preinjected with 1 mg of trastuzumab dissolved in 0.1 mL of 0.9% NaCl solution, 1 h prior to the administration of the imaging agent. At 48 h after the administration of the imaging agent, mice were anesthetized with isoflurane (2.5%, 0.4 L/min oxygen) and subsequently euthanized using carbon dioxide. The organs of interest were collected, excess blood was rinsed off, weighed, and assessed on a gamma-counter together with injection standards. The percentage of injected per gram (%ID/ g) was calculated for each tissue. The tumor-to-tissue ratios were also determined.
In vivo biodistribution of
Data analysis
All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) software. The data are expressed as x±s. Between-group differences were evaluated using Student's t test, and P<0.05 was considered statistically signifi cant.
Results
Preparation of dual-labeled imaging conjugate
A series of (DTPA) n -trastuzumab and (DTPA) 2 -trastuzumab-(IRDye 800) m were successfully prepared as described in this section. The chelator-to-trastuzumab ratios used for (DTPA) n -trastuzumab were 1.03, 2.12, 3.05 and 5.18; the dyeto-protein ratios used for (DTPA) 2 -trastuzumab-(IRDye 800) m were 1.06, 3.03 and 4.71.
Purity of (DTPA) 2 -trastuzumab-(IRDye 800) m
The relative amount of unconjugated IRDye 800CW was determined via SDS-PAGE and fl uorescence imaging system. The location of free IRDye 800CW in the gel (approximately 1 kD) was similar to that of bromophenol blue (approximately 0.5 kD). The purity of (DTPA) 2 -trastuzumab-(IRDye 800) 1 , (DTPA) 2 -trastuzumab-(IRDye 800) 3 and (DTPA) 2 -trastuzumab-(IRDye 800) 5 is presented in Figure 1 , no free dye band was observed in the purified conjugates, and <3% of the fluorescent signal was associated with larger molecules (>250 kD).
Radiolabeling and stability
The radiolabeling yield of trastuzumab-based radiotracers ranged between 85% and 100% at a specific activity of approximately 370-740 mBq per mg protein as demonstrated by SG-ITLC analysis. After the purifi cation of radiotracers, no free radioactive band was detected on gel scanning with Bioscan System (Figure 2) , and a main radioactive band (approximately 150 kD) was displayed for each radiolabeled trastuzumab-based conjugate.
The optical stability of 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) m in PBS and human serum was demonstrated using a LI-COR Odyssey near-infrared imaging system. The IRDye 800 signal remained constant in PBS after 24 h but not in human serum (Figure 3) . After 24 h, large proteins (>150 kD) were found on the gel for all three conjugates ( Figure 3) . Similar results were obtained on scanning of SDS-PAGE gels with the Bioscan system (Figure 4) . The extra radioactive peak, which corresponded to the higher molecular weight proteins, can be observed in the histograms of dual-labeled conjugates. The larger the dye-to-protein ratio, the greater the amount of >150 kD proteins were found in the conjugate solution.
Immunoreactivity assay
The FACS histogram for SKBR-3 cells incubated with (DTPA) 1 -trastuzumab, (DTPA) 2 -trastuzumab, (DTPA) 3 trastuzumab and (DTPA) 5 -trastuzumab at the same concentration was comparable to that of trastuzumab, which suggests that the DTPA-to-trastuzumab ratios of 1 to 5 had minimal effect on immunoreactivity ( Figure 5 ). However, the FACS histogram of (DTPA) 2 -trastuzumab-(IRDye 800) 1 showed a slight reduction in fl uorescent intensity, which indicates reduced immunoreactivity as compared to that of (DTPA) 2 -trastuzumab. In contrast, the immunoreactivity of (DTPA) 2 -trastuzumab-(IRDye 800) 5 was moderately impaired, as evidenced in the clear shift of the histogram toward the negative control population of SKBR-3 cells. The immunoreactivity of (DTPA) 2 -trastuzumab-(IRDye 800) 3 Figure 6 illustrates the specifi c internalization of In-(DTPA) 2 -trastuzumab-(IRDye 800) 5 was higher than that of the other two. However, the percentages of internalization corresponding to "m" values of 1, 3 and 5 after the normalization of the total fl uorescence intensities of dual-labeled conjugates by the dye-to-protein ratio were 24.88%±2.10%, 19.99%±0.59% and 17.47%±1.26% at 4 h, respectively.
Internalization study
The intensity of internalized radioactivity corresponding to "m" values of 0, 1, 3 and 5 was comparable to the results presented above, i.e., 26.34%±0.03%, 23.87%±0.02%, 21.07%±0.01% and 20.45%±0.01% at 4 h, respectively.
Biodistribution study
The biodistribution of 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) m in SKBR-3 tumor-bearing nude mice was assessed at 48 h, and the data are summarized in Table 1 The excretion of dual-labeled conjugates was largely via the kidney and liver, particularly the former. The renal uptake of 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) 5 was 28.37±4.55 %ID/g, which is much higher than that of 111 In-(DTPA) 2 -trastuzumab (5.43±2.42 %ID/g), and the liver uptake of both conjugates was comparable (approximately 8 %ID/g at 48 h post-injection).
Discussion
Dual-labeling of targeting moieties with nuclear and fluorescent entities provides a non-invasive modality for the localization of lesions with the use of highly penetrative, shortlived radionuclides and then uses the fluorescence signals from optical molecular probes allowing for disease monitoring over prolonged periods of time to guide surgical resection (5, 13) . Furthermore, the use of dual-labeled targeting tracer effectively avoids issues related to the use of agents with differing pharmacokinetic and pharmacodynamic properties that may otherwise affect image fusion and its interpretation (17) . However, the development of dual-labeled targeting pharmaceuticals is a multistep and technically more challenging technique that requires complex design considerations such as careful selection of nuclear and optical tracers to minimize physical-chemical interference between various molecular components. Thus, the modification of the moiety to the maximum extent possibly whilst ensuring that the modifi cation does not compromise bioactivity is of considerable interest (15, 18) . In our studies, we have used trastuzumab as a targeting moiety that is covalently linked to IRDye 800CW, a NIR fluorescent dye, and DTPA, a chelator of 111 In, to develop a dual-labeled imaging agent to trace HER-positive primary breast lesions and metastases.
Previous studies have demonstrated dimer and polymer formation with an increase in the DTPA anhydride to antibody ratio, which resulted in a decreased biological affinity of the conjugate relative to the unlabeled antibody (15) . However, Forrer et al. found no significant difference in the immunoreactivity between (DOTA) 4 -rituximab immunoconjugate and a commercially available rituximab on lymphoma cell line LVB1 (19) . Our FACS results showed no signifi cant difference in immunoreactivity between trastuzumab and the singly labeled DTPA conjugates up to a chelator-toprotein ratio of 5:1. Furthermore, a 1:1 molar ratio of DTPA to protein was not suffi cient for prompt labeling with the needed amount of 111 In (e.g., approximately 370-740 mBq per mg of antibody). Based on radiolabeling yields, specifi c radioactivity, solubility and immunoreactivity, we employed a molar DTPAto-trastuzumab coupling ratio of 2:1 in this study.
As with radionuclide conjugation, dye-to-protein ratio is also liable to impact in vivo signal levels. A low dye-to-antibody ratio will reduce fl uorescence intensity, while over-conjugation on non-specifi c sites of the protein may cause self-quenching of the dye as well as the loss of biological activity. Gee et al. synthesized (Cy5.5) m -trastuzumab with molar ratios of the dye to protein ranging from 0.5 to 2.0 (20) . A molecular dye to antibody ratio of 1.1 was found to be optimal based on the binding affi nity. The use of higher dye-to-antibody ratios was found to decrease immunoreactivity, while a probe containing a lower dye-to-antibody ratio (0.5) was associated with reduced fl uorescence intensity.
We synthesized (DTPA) 2 -trastuzumab, (DTPA) 2 -trastuzumab-(IRDye 800) 1 , (DTPA) 2 -trastuzumab-(IRDye 800) 3 and (DTPA) 2 -trastuzumab-(IRDye 800) 5 to investigate the influence of dye-to-protein ratios on the affinity, stability and the in vivo targeting potential for near-infrared fluorescence imaging. The binding affinity of the immunoconjugates was tested in HER2-overexpressing SKBR-3 tumor cells and immunoreactivity assessed using FACS. The representative histogram shows a decrease in MFI corresponding to an increase in the dye-to-protein ratios. The successive percentage of immunoreactivity fell from 100% (without any dye on the antibody) to 83%, at a molar dye-toprotein ratio of 1:1, which demonstrates a high affi nity of the duallabeled conjugate for binding to HER2 on breast cancer cells. At molar dye-to-protein ratios of 5:1, a 42% loss of immunoreactivity was observed. Furthermore, the formation of large proteins (>150 kD) was observed with all three dual-labeled conjugates after incubation with human serum for 24 h. The larger the dye-toprotein ratio, the greater the amount of >150 kD proteins found in the conjugate solution.
To the best of our knowledge, the relationship between the dye-to-protein ratio and specific binding affinity has only been investigated in vitro, because quantitative measurement of tissue fluorescence is liable to be affected by variability in tissue absorption properties and scattering of fl uorescent signals. Li et al. compared the biodistribution of 111 In-labeled c (KRGDf) peptide and dual-labeled c (KRGDf) peptide, both of which targeted α ν β 3 integrin in melanoma xenografts, with a 1:1 molar ratio of chelator and fl uorophore, using tissue radioactivity measurements (21) . We evaluated the relationship of the dye-to-protein ratio with specifi c targeting using nuclear medicine techniques.
As compared to the biodistribution of 111 In-(DTPA) 2 -trastuzumab, the percentage of HER2(+) tumor accumulation also decreased significantly (P<0.05) with increasing dyeto-protein molar ratios, which is consistent with our in vitro findings. Tumor uptake decreased from 15.76±2.61 %ID/g for 111 In-(DTPA) 2 -trastuzumab to 6.77±1.73 %ID/g for 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) 5 , which represents an approximate 57% reduction. Furthermore, the renal uptake increased from 5.43±2.42 %ID/g for 111 In-(DTPA) 2 -trastuzumab to 28.37±4.55 %ID/g for 111 In-(DTPA) 2 -trastuzumab-(IRDye 800) 5 , which is partly attributable to the decreased conjugate stability.
Conclusions
Dual-labeled trastuzumab conjugates were successfully coupled with DTPA and IRDye 800CW. Increasing dye-to-protein ratios decreased immunoreactivity and serum stability, and lowered tumor accumulation.
